RxDoctor Payments Data

Hugh Jarnagin

Family · Knoxville, TNNPI 1801349626

Payments from drug & device makers

$6,318in general payments, 2019–2025

Across 275 payments — averaging $22.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$883
  • AbbVie$701
  • CSL Behring$548
  • AstraZeneca$360
  • Biogen$219
  • Neurelis, Inc.$205
  • plus $3K from 48 others

What the payments were for

  • Food & beverage$6,318100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,318 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$20,088
Medicare patients
232
Services billed
302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)63$191,021
Nurtec OdtRimegepant Sulfate76$79,001
FycompaPerampanel50$71,829
BriviactBrivaracetam45$62,503
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$62,304
Emgality PenGalcanezumab-Gnlm71$57,622
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5011$55,069
AptiomEslicarbazepine Acetate28$53,987
VimpatLacosamide32$39,378
NuedextaDextromethorphan Hbr/Quinidine25$38,956
Topiramate ErTopiramate26$31,495
UbrelvyUbrogepant23$29,971
Oxtellar XrOxcarbazepine16$27,695
QuliptaAtogepant23$26,239
Lacosamide220$25,829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat, Nayzilam$883$111,32192 claims
PfizerNurtec Odt, Dilantin$70$91,309135 claims
Eisai Inc.Fycompa$108$71,82950 claims
Grifols USA, LLCGamunex-C$113$62,30415 claims
AbbVieUbrelvy, Qulipta$701$56,21046 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$204$55,06911 claims
Sunovion Pharmaceuticals Inc.Aptiom$32$53,98728 claims
SK Life Science, Inc.Xcopri$117$25,70312 claims
E.r. Squibb & Sons, L.L.C.Abilify$63$14,74912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.

Other family in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →